Integrated Gut Microbiota and Urine Metabolite Analyses of T2DM with NAFLD Rat Model

被引:0
|
作者
Jinghua Qin
Xue Ling
Qianyi Wang
Zheng Huang
Bingjian Guo
Chi Zhang
Mingwei Meng
Shisui Feng
Yue Guo
Hua Zheng
Yonghong Liang
Zhiheng Su
机构
[1] Guangxi Medical University,Pharmaceutical College
[2] Guangxi Institute of Traditional Medical and Pharmaceutical Sciences,Guangxi Key Laboratory of Traditional Chinese Medicine Quality Standards
[3] Life Sciences Institute,undefined
[4] Guangxi Medical University,undefined
[5] Guangxi Key Laboratory of Bioactive Molecules Research and Evaluation,undefined
[6] Guangxi Engineering Research Center for Beibu Gulf Marine Biomedicine Precision Development and High-Value Utilization,undefined
[7] Guangxi Health Commission Key Laboratory of Basic Research On Antigeriatric Drugs,undefined
来源
关键词
T2DM with NAFLD; 16S rRNA gene sequencing; Gut microbiota; Metabolomics; Metabolites;
D O I
暂无
中图分类号
学科分类号
摘要
Globally 80% type 2 diabetes mellitus (T2DM) patients suffer nonalcoholic fatty liver disease (NAFLD). The interplay of gut microbiota and endogenous metabolic networks has not yet been reported in the setting of T2DM with NAFLD. As such, this study utilized 16S rRNA gene sequencing to assess the changes in intestinal flora and nuclear magnetic resonance spectroscopy (1H NMR) to identify potential metabolites in a T2DM with NAFLD rat model. Spearman correlation analysis was performed to explore the relationship between gut microbiota and metabolites. Results revealed that among T2DM with NAFLD rats, diversity indexes of intestinal microbiota were distinctly decreased while levels of 18 bacterial genera within the intestinal tract were significantly altered. In addition, levels of eight metabolites mainly involved in the synthesis and degradation of ketone bodies, the TCA cycle, and butanoate metabolism were altered. Correlation analysis revealed that gut bacteria such as Blautia, Ruminococcus torques group, Allobaculum, and Lachnoclostridium strongly associate with 3-hydroxybutyrate, acetone, acetoacetate, 2-oxoglutarate, citrate, creatinine, hippurate, and allantoin. Our findings can provide a basis for future development of targeted treatments.
引用
收藏
页码:6478 / 6494
页数:16
相关论文
共 50 条
  • [21] PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD
    Barbara Gross
    Michal Pawlak
    Philippe Lefebvre
    Bart Staels
    [J]. Nature Reviews Endocrinology, 2017, 13 : 36 - 49
  • [22] Relationship between NAFLD and Cardiac Complications and Function in T2DM
    Lavrynenko, Olga
    Zemlianitsyna, Olha
    Dunaeva, Inna
    Kravchun, Nonna
    Sinaiko, Vadym
    Defronzo, Ralph A.
    [J]. DIABETES, 2020, 69
  • [23] Is NAFLD an independent risk factor for increased IMT in T2DM?
    Cakir, E.
    Ozbek, M.
    Colak, N.
    Cakal, E.
    Delibasi, T.
    [J]. MINERVA ENDOCRINOLOGICA, 2012, 37 (02) : 187 - 193
  • [24] Causal relationship between T2DM microvascular complications and gut microbiota: a Mendelian randomization study
    Zhang, Junping
    Yu, Zilu
    Li, Shanshan
    Zhang, Qingfang
    Chen, Wen
    Wang, Jingying
    He, Shasha
    Liu, Ying
    Chen, Shen
    Xu, Jixiong
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [25] Translational Research into Human Gut Microbiota in Non-Diabetes, Prediabetes (Pre-DM), and Type 2 Diabetes (T2DM)
    Ramaraj, Thiruvarangan
    Bell, Callum
    Leff, Jonathan
    Lambeth, Stacey
    Carson, Trechelle
    Lowe, Janae
    Shah, Vallabh
    [J]. DIABETES, 2014, 63 : A424 - A424
  • [26] Are Plasma Aminotransferases of Value in Screening Patients with T2DM for NAFLD or Fibrosis?
    Rocha, Andrea Ortiz
    Leiva, Eddison Godinez
    Kalavalapalli, Srilaxmi
    Lomonaco, Romina
    Shetty, Shwetha S.
    Marangi, Stephen A.
    Saenz, Enrique Valdez
    Shrestha, Sulav
    Gonzalez, Maria A.
    Chi, Xiaofei
    Gurka, Matthew J.
    Barb, Diana
    Cusi, Kenneth
    [J]. DIABETES, 2023, 72
  • [27] T2DM患者合并NAFLD的危险因素分析
    董迎
    张雯
    [J]. 继续医学教育, 2012, 26(Z1) (Z1) : 71 - 74
  • [28] Correlation study on gut microbiota and dietary intake of new-onset T2DM and IGR patients
    Rebiya, Nuli
    Cai, Junxiu
    Aizhatiguli, Kadeer
    Shan, Jiaoyu
    Zhang, Bing
    Patamu, Mohemaiti
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2018, 34
  • [29] Identification of a novel metformin-methylglyoxal imidazolinone metabolite in T2DM patients and its potential roles in alleviating T2DM complications
    Hargraves, Tiffanie Leann
    Kinsky, Owen R.
    Monks, Terrence J.
    Lau, Serrine S.
    [J]. FASEB JOURNAL, 2017, 31
  • [30] Gymnema sylvestre extract ameliorated streptozotocin-induced hyperglycemia in T2DM rats via gut microbiota
    Chen, Guilin
    Xu, Yongbing
    Zhang, Hui
    Muema, Felix Wambua
    Guo, Mingquan
    [J]. FOOD FRONTIERS, 2023, 4 (03): : 1426 - 1439